百克生物1月29日获融资买入669.49万元，融资余额2.09亿元

Group 1 - On January 29, Baike Bio's stock fell by 0.73%, with a trading volume of 64.41 million yuan [1] - The financing data for Baike Bio on the same day showed a financing purchase amount of 6.69 million yuan and a financing repayment of 11.43 million yuan, resulting in a net financing outflow of 4.74 million yuan [1] - As of January 29, the total balance of margin trading for Baike Bio was 210 million yuan, with the financing balance accounting for 2.49% of the circulating market value, indicating a low level compared to the past year [1] Group 2 - As of September 30, Baike Bio had 10,800 shareholders, an increase of 7.23% from the previous period, while the average circulating shares per person decreased by 6.74% to 38,216 shares [2] - For the period from January to September 2025, Baike Bio reported an operating income of 474 million yuan, a year-on-year decrease of 53.76%, and a net profit attributable to shareholders of -158 million yuan, a decline of 164.76% [2] - Since its A-share listing, Baike Bio has distributed a total of 235 million yuan in dividends, with 194 million yuan distributed over the past three years [2]